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Objective: Cervical cancer (CC) screening by Pap smears has led to a decrease in 
the incidence of CC worldwide. Indeed, the incidence of CC in Switzerland is very low; 
however, there is a lack of data to evaluate the efficiency of the Pap smear as a screening 
tool. Until now, only Pap smears have been used and other methods such as the pres-
ence of an infection with HPV have not been integrated into the routine screening. The 
aim of this study is to evaluate trends in the incidence of CC and its precancerous lesions 
in Central Switzerland, which represents a rural region, with those in urban regions and 
the entire country of Switzerland.
Methods: All conizations and CC registered between 2000 and 2014 at the Institute 
of Pathology at the Cantonal Hospital of Lucerne have been included in our study. The 
incidence of CC and its precancerous lesions have been categorized according to age, 
stage, morphology, and study period. Age-standardized incidence in the Canton of 
Zurich and the entire country served as reference for the assessment of trends in CC 
incidence in the study region.
results: In Central Switzerland, the number of conizations performed annually has 
more than doubled over the observed 15 years. There has been a significant increase 
in precancerous lesions, which were found in approximately 50% of conizations. The 
total number of CC diagnosed by conization increased by 37.5% and the total of CIN3 
increased by 130%. Age-standardized incidence of CC and CIN3 increased from 2.4 
to 3.3/100,000 and from 11.6 to 26.9/100,000, respectively. The incidence of CC was 
lower in Central Switzerland compared to incidence in the Canton of Zurich and in 
Switzerland generally.
conclusion: Approximately 50% of all conizations were performed on women with-
out serious precancerous lesions. For this reason, we recommend the adaptation of 
screening modalities and the use of risk stratification to avoid overtreatment. In light 
of the forthcoming implementation of an HPV vaccination program, our data provides 
important baseline information.
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inTrODUcTiOn
Since the inception of cervical cancer (CC) screening by regular Pap 
smears, the incidence of CC has decreased significantly worldwide. 
Since the 1980s, the incidence of CC was reduced by almost 50% 
in Switzerland. Nowadays, there is an incidence of 3.6/100,000 in 
Switzerland, which constitutes a very low rate within the European 
context (e.g., Germany had an incidence of 8.2/100,000 in 2012) 
(1). The current guidelines for CC screening in Switzerland recom-
mend that for women with abnormal cytology in the Pap smear, the 
performance of a colposcopy, and if the finding looks abnormal a 
biopsy. Women with a pathological cytology indicating high-grade 
squamous intraepithelial lesion or pathology [high-grade cervical 
intraepithelial lesion (CIN) or adenocarcinoma (AC) in situ] are 
treated by conization (2). There is no valid data available on the 
amount of conizations performed in Switzerland, but it is esti-
mated at 3,000 per year (3). The proportion of different findings in 
conizations is unknown and there is also a lack of information on 
CC occurrence in rural and urban regions of Switzerland.
The main aim of this study is to assess the incidence of CC 
and its precancerous lesions in Central Switzerland. We evaluated 
changes regarding histological subtypes of CC, proportion of CC 
diagnosed through conization as well as mean age at time of diag-
nosis of CC or performance of conization. As Central Switzerland 
is a rural area, trends in CC incidence in the study region were 
compared with data for all of Switzerland and for the Canton of 
Zurich, to compare rural and urban parts of Switzerland.
MaTerials anD MeThODs
Data sources
Data were provided by the Institute of Pathology at the Cantonal 
Hospital of Lucerne, which receives its samplings from the 
Cantons of Central Switzerland including Lucerne, Obwalden, 
Nidwalden, Uri, Schwyz, and Zug. In 2014, Central Switzerland 
had 782.374 residents, representing 9.5% of the Swiss population.
All 174 cases of CC registered at the Institute of Pathology at 
the Cantonal Hospital of Lucerne between 2000 and 2014 were 
analyzed. Data included year and age at time of diagnosis, his-
topathological type, nationality, and FIGO stage (4). FIGO stage 
was divided into four categories: FIGO IA, IB, II, and >II. In three 
cases, data on FIGO stage were not available. Histopathological 
type was classified into three categories: squamous cell carcinoma 
(SCC), AC, and other types. We classified adenosquamous car-
cinoma, adenoid cystic carcinoma, neuroendocrine carcinoma, 
and cervical carcinosarcoma as other types.
Furthermore, we analyzed all conizations registered between 
2000 and 2014 at the Institute of Pathology at the Cantonal 
Hospital of Lucerne (n = 2,005). Data included findings as well 
as year and age at time of conization. Results were classified as 
negative for dysplasia or malignancy, CIN1, CIN2, CIN3, and CC.
To evaluate whether our institution-based data represented 
the population-based incidence rate of Central Switzerland, we 
compared data of the Swiss national dataset managed by the 
National Institute for Cancer Epidemiology and Registration 
(NICER) to data of the Institute of Pathology at the Cantonal 
Hospital of Lucerne.
The comparison had to be restricted to the years between 2010 
and 2012 since the population-based cancer registry for Central 
Switzerland has only been established very recently. Although 
the region of Central Switzerland usually includes the Cantons 
of Lucerne, Nidwalden, Obwalden, Uri, Schwyz, and Zug, the 
population-based cancer registry of Central Switzerland com-
prises only the Cantons of Lucerne, Nidwalden, Obwalden, and 
Uri but not Schwyz and Zug. Both numerators and denominators 
for the calculation of population-based incidence rates have been 
adjusted accordingly and pertain to Central Switzerland exclud-
ing Schwyz and Zug. To find out if there are similar trends in CC 
incidence, we compared age-standardized incidence rates (ASIR) 
of CC in Central Switzerland (excluding Schwyz and Zug) with 
the corresponding ASIR in Switzerland, extracted from the Swiss 
national dataset managed by NICER. A very recent and extensive 
evaluation demonstrated high completeness across all registries 
and for most cancer types including CC (5). In addition, to 
analyze if there is a difference in ASIR of CC between rural and 
urban regions of Switzerland, we compared population-based 
data of Central Switzerland (excluding Schwyz and Zug) with 
data of the Canton of Zurich, also provided by NICER. According 
to the list of “areas with urban character 2012” compiled by the 
Swiss Federal Statistical Office, the Canton of Zurich belongs to 
an area with urban characteristics whereas most parts of Central 
Switzerland belong to the rural area of Switzerland (6). Data for 
Switzerland and the Canton of Zurich were only available for the 
time period between 2000 and 2013.
Cases from the Cantons of Zug and Schwyz were excluded from 
analysis due to potential underrepresentation in the database of 
the Cantonal Hospital of Lucerne. Presumably, underrepresenta-
tion is due to the fact that women from these two cantons went 
to Zurich for treatment since Zug and Schwyz are very close to 
Zurich. Furthermore, according to the FSO, the Cantons of Zug 
and Schwyz do not constitute rural areas.
Ethical approval is not required because of the retrospective 
character of the study. We used anonymized datasets only.
statistical analysis
Patients were classified into the following age groups: <29, 30–39, 
40–49, 50–59, 60–70, and >70 years. ASIR for CC and CIN3 were 
calculated for every year in the period between 2000 and 2014 
using the European standard population. For the descriptive 
analysis, cases were stratified into 5-year time periods (2000–2004, 
2005–2009, and 2010–2014). Poisson regression was used to test 
for linear trend in 5-year incidence of CC and CIN3. The data 
analysis was carried out using SPSS statistical software (Statistical 
Package for Social Sciences, version 22.0, SPSS Inc., Chicago, IL, 
USA). The Kruskal–Wallis test was conducted to test for signifi-
cance of mean age and FIGO stage as well as mean age and degree 
of dysplasia in conizations. The significance level was set at 5%.
resUlTs
Trends in Findings in conizations in 
central switzerland
Between 2000 and 2014, a total of 2005 conizations were performed 
in Central Switzerland. Overall, 272 conizations (13.6%) showed 
negative for dysplasia 
14% 
CIN I 
11% 
CIN II 
22% 
CIN III 
50% 
CC 
3% 
FigUre 1 | Findings in conizations in Central Switzerland, 2000–2014. In 
total, 272 conizations showed no evidence of dysplasia, 220 showed CIN1, 
443 CIN2, 1,000 CIN3, and 70 showed cervical cancer (CC).
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FigUre 2 | Number and proportions of dysplastic findings and cervical cancer (CC) diagnosed by conization in Central Switzerland, 2000–2014. There is a 
significant increase of conizations (n = 2,005) as well as CIN3 and CIN2 diagnosed by conization (p-value < 0.001, respectively). CC shows a stable course.
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no evidence of dysplasia, 220 (11.0%) were classified as CIN1, 
443 (22.1%) as CIN2, 1,000 (49.9%) as CIN3, and 70 (3.5%) as 
CC (Figure 1). The annual number of conizations (range 66–262) 
sharply increased during the study period (p-value <  0.001). 
Also, the absolute number of CIN3, CIN2, CIN1, and findings 
without dysplasia increased proportionally. Only the proportion 
of invasive CC decreased from around 5% at the beginning to 
around 2% at the end of the study period (Figure 2).
The mean age of women at time of conizations was 36.0 years 
(range 18–81 years), but varied according to degree of dysplasia 
(p-value < 0.001). Invasive CC and conizations with no evidence 
of dysplasia were found more often in older women (median 41.1 
and 40.3 years). Mean age at time of diagnosis of CIN1, CIN2, and 
CIN3 was comparable with 35.5 vs. 34.7 vs. 35.2 years.
incidence Trends of invasive cc and 
Precancerous lesions in conizations in 
central switzerland
During the period between 2000 and 2014, 174 cases of CC were 
registered for Central Switzerland, corresponding to an ASIR 
of 2.9/100,000 females. CC incidence increased by 37.5% from 
2.4/100,000 between 2000 and 2004 to 3.3/100,000 between 2010 
and 2014 (p-value 0.075). Out of 174 CC, 134 cases were histo-
pathologically classified as SCC (77.0%), 32 as AC (18.4%), and 8 
as other subtypes of CC (4.6%). No significant change occurred 
in any of the subtypes over the course of the observed 15 years. 
In the same time, a total of 1,000 cases with CIN3 were diagnosed 
(ASIR 17.8/100,000). The incidence of CIN3 increased from 
11.6/100,000 between 2000 and 2004 to 26.9/100,000 between 
2010 and 2014 (+130%, p-value < 0.001) (Figure 3).
Trends in cc Diagnosed by conization in 
central switzerland
Cervical cancer was diagnosed by conization in 70 cases (40.2% 
of CC). The proportion of CC diagnosed by conization decreased 
from 46.7% between 2000 and 2004 to 40.0% between 2005 and 
2009 to 36.2% between 2010 and 2014 (p-value 0.828). If CC 
was diagnosed by conizations, histological findings more often 
showed SCC (85.7 vs. 71.1%) and more rarely AC (11.4 vs. 23.1%) 
(OR = 2.43, p = 0.04). Irrespective of histological subtype, patients 
Table 1 | Number and mean age of histological subtypes of cervical cancer (CC) depending on type of diagnosis, CC diagnosed by conization and CC diagnosed 
other than by conization.
cc cc n.s. cc in conization
number (%) Mean (years) number (%) Mean (years) number (%) Mean (years)
Total 174 48.5 104 53.4 70 42.1
Squamous cell carcinoma 134 (77.0) 47.7 74 (71.1) 52.8 60 (85.7) 41.4
Adenocarcinoma 32 (18.4) 49.1 24 (23.1) 52.9 8 (11.4) 37.9
Others 8 (4.6) 59.3 6 (5.8) 62.7 2 (2.9) 49.0
There is no significant difference in age at time of diagnosis between the histological subtypes in all observed CC (p-value 0.078) or CC diagnosed by conization (p-value 0.279). (ns: 
diagnosis not elsewhere specified, diagnosis not performed by conization.)
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FigUre 3 | Trends in age-standardized incidence of cervical cancer (CC) and CIN3 in conizations in Central Switzerland, 2000–2014. There is a trend toward 
increasing age-standardized incidence rates (ASIR) of CC (p-value 0.075) and a significant increase of ASIR of CIN3 (p-value < 0.001). There is no significant 
increase of ASIR of squamous cell carcinoma (SCC) from 1.8/100,000 between 2000 and 2004 to 2.4/100,000 between 2005 and 2009 and between 2010 and 
2014 (p-value 0.132) and of adenocarcinoma (AC) from 0.4/100,000 between 2000 and 2004 to 0.6/100,000 between 2005 and 2009 to 0.9/100,000 between 
2010 and 2014 (p-value 0.423).
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whose CC was diagnosed in the context of a conization were 
approximately 12 years younger than other CC patients (Table 1).
Trends in cc Depending on FigO stage in 
central switzerland
Overall, CC was diagnosed in FIGO IB in 40.8% of all CC cases. 
FIGO IA was found in 24.7%, FIGO II in 19.5%, and FIGO >II 
in 13.2%. The proportion of cases diagnosed with FIGO >II 
increased from 2 to 23% in the course of the 15-year study period 
(p-value  <  0.001) (Figure  4). If diagnosis was performed by 
conization, the most frequent FIGO stage was FIGO IA (57.1%), 
followed by FIGO IB (40.0%) compared to diagnosis other than 
conization, which was diagnosed the most frequent in FIGO 
IB (41.3%) followed by FIGO II (31.7%). CC in FIGO IA was 
diagnosed by conization in 93.0% of cases. Women diagnosed 
with CC in FIGO IA were youngest, with 42.0 years, followed by 
FIGO IB with 45.6 years, FIGO II with 55.5 years, and FIGO >II 
with 60.4 years (p-value < 0.001).
comparison of cc incidence between 
central switzerland and switzerland and 
between rural and Urban Parts of 
switzerland
Incidence of CC in the period between 2000 and 2013 was 
lower in Central Switzerland (ASIR 3.7/100,000 females) than 
in Switzerland overall (ASIR 5.8/100,000 females) or in the 
Canton of Zurich (ASIR 6.0/100,000 females). Over the course 
of the observed time period, CC incidence declined in all of 
Switzerland as well as in the Canton of Zurich. Trends and 
the extent of CC incidence in these two regions were almost 
identical. By contrast, incidence of CC in Central Switzerland 
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FigUre 4 | Trends in number of histological subtypes of cervical cancer (CC) by FIGO stage at time of diagnosis, Central Switzerland 2000–2014. There is 
a trend of increasing numbers of findings with FIGO IA (p-value 0.077) and a significant increase of findings FIGO >II (p-value < 0.001). If CC was diagnosed 
in FIGO IA, adenocarcinoma (AC) was found in 9.8% and squamous cell carcinoma (SCC) in 90.0%, compared to FIGO IB with 29% of AC and 71% of 
SCC.
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FigUre 5 | Trends in age-standardized incidence rates (ASIR) of cervical cancer (CC) in Switzerland, the Canton of Zurich and Central Switzerland. There are similar 
trends in ASIR of CC in Switzerland and in the Canton of Zurich over the course of the observed time. CC incidence in Central Switzerland was lower in earlier years, 
but all rates converged in 2012/2013 (Central Switzerland: 4.8/100,000, Switzerland: 5.1/100,000, and Canton of Zurich: 5.3/100,000).
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was generally lower. There was, however, a tendency to increase 
over the years. In 2012/2013, the incidence rates of the three 
study regions converged (Figure 5). CC incidence rates between 
2010 and 2012 in Central Switzerland, provided by NICER, and 
rates based on cases reported to the Institute of Pathology at the 
Cantonal Hospital Lucerne were identical (ASIR 3.8/100,000), 
indicating comparable population-based coverage for the study 
region.
6Ochs et al. CC in Central Switzerland
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DiscUssiOn
Our data shows an extremely low incidence rate of CC com-
pared to worldwide standards (1). In contrast to global trends, 
we found an upward trend of CC occurrence over the course 
of the observed 15  years (7–9). Compared to Switzerland 
as a whole and to the Canton of Zurich, which represents an 
urban part of Switzerland, the incidence rates of CC were low 
in Central Switzerland. This low incidence might be related 
to a smaller percentage of immigrants in Central Switzerland 
(median of 16.1%), as compared to the Canton of Zurich and 
to Switzerland (22.9 and 21.1%, respectively) (10). Likewise, 
differences in spread of risk factors for CC (e.g., contamination 
with HPV) or levels of participation in screening programs in 
relation to education and income levels might be discussed, but 
pertinent data are lacking. Data regarding the spread of HPV in 
Switzerland have been recently described in the CIN3+-study, 
but only six cantons had participated in it (11). The study shows 
that 61.8% of cervical biopsies were positive for HPV 16 and 18, 
and 89.5% of biopsies showed positive results for HPV-types, 
which are included in the nonavalent vaccine (HPV 16, 18, 31, 
33, 45, 52, and 58). Unfortunately, this vaccine is not available in 
Switzerland yet. There are currently two HPV vaccines available. 
A bivalent vaccination targets HPV 16 and 18 and a quadriva-
lent vaccination targets HPV 6, 11, 16, and 18. Data obtained 
from large cohorts of women several years after implementation 
of bivalent (12) or quadrivalent (13) vaccination showed high 
efficacy against infections due to HPV type 16 and 18 as well 
as anogenital warts. It is obvious that HPV vaccination affects 
CC screening and screening modalities must be reconsidered in 
terms of adding HPV testing to cytology as primary screening or 
replace it. Until now, an HPV-based screening is not approved 
by the government in Switzerland.
A limitation of our analysis is the relatively small sample size 
of women diagnosed with CC and consequently low power. 
In addition, our data only shows the number of precancerous 
lesions diagnosed by conization while the absolute number of 
precancerous lesions in Central Switzerland is not analyzed. We 
assume this number to be very small. It is reasonable to assume 
that these women underwent off-label-use therapies based on 
imiquimod or similar treatments. The selection bias, too, may be 
deemed detrimental to the significance of the study. In interpret-
ing the data from registry-based and institution-based datasets, 
the limitations of retrospective analyses must be considered in 
terms of cleanliness and completeness. However, we did succeed 
in proving that the institution-based data for Central Switzerland 
provided by the Institute of Pathology at the Cantonal Hospital of 
Lucerne is similar to the estimates derived from the official Swiss 
national dataset managed by NICER.
Our analysis shows a vast increase of conizations over the 
observed 15 years. The number of conizations more than doubled. 
However, the female population shows only a small increase of 
13% (10). In total, we diagnosed a significant increase of precan-
cerous lesions as well as of findings without dysplasia. But if we 
look at the amount of findings relative to the increased number of 
conizations, we find a constant proportion of CIN3, CIN2, CIN1, 
and samplings without dysplasia. It is only the proportion of CC 
diagnosed by conizations, which is decreasing. Consequently, 
the increased number of conizations seems to be justified. 
Considering the increasing number of samplings with CIN3 as 
an expression of improvement in quality in CC screening, the 
amount of CIN1 and CIN2 should decrease as well. This means 
that there is an overtreatment regarding the samplings with CIN1 
and CIN2. The question arises whether the overtreatment is a 
result of incorrect material recovery, workup or assessment in Pap 
smears, biopsy or cone biopsy, or instead attributable to ignored 
guidelines.
It is reported that Pap smear screening seems to be less effec-
tive for AC detection than for SCC (7, 14, 15). Our results confirm 
this assertion. Comparing the different histological subtypes, less 
AC is diagnosed by conizations and, in addition, AC is frequently 
diagnosed at more advanced stages. The current guidelines of the 
Swiss Society of Obstetrics and Gynecology recommend age-
appropriated screening programs through Pap smears. The use 
of HPV testing in screening strategies is not yet routinely recom-
mended. HPV testing is only recommended to be used in cases of 
atypical squamous cell of undetermined significance and atypical 
glandular cells of undetermined significance (2). However, the 
guidelines of the American Society for Colposcopy and Cervical 
Pathology from 2012 recommend co-testing with HPV testing 
and cytology every 5 years between 30 and 64 years (16). HPV 
testing is known to be more sensitive, but less specific than cytol-
ogy for the detection of cervical precancerous lesions (17). Recent 
studies show that with the addition of HPV testing to cytology, 
high-grade lesions are detected earlier and the incidence of grade 
2 or 3 intraepithelial neoplasia or cancer can be reduced (18). This 
results in longer screening intervals with similar or even lower 
incidence cancer rates compared to cytology alone at shorter 
screen intervals (19–21). Recent studies have also reported that 
the addition of HPV testing to cytology increases the detection of 
women with AC and its precursors (22, 23).
Less than half of CC was diagnosed by conization and the 
number of CC diagnosed in an advanced stage of cancer has 
been increasing. The question is, however, what are the reasons 
behind the large number of CC not diagnosed by conizations. 
It may either be due to failures in the diagnostic chain or the 
result of many women not participating in cervical screening 
programs. Our data supports the assumption that women at 
risk do not participate in the screening programs and are then 
only diagnosed in advanced stages of CC. Studies have shown 
that organized CC screening achieves high quality standards 
and greater participation among the target population (24, 
25). However, the implementation of an organized screening 
program might hardly be possible in a federal country like 
Switzerland.
In conclusion, our data shows that a high number of coniza-
tions are performed unnecessarily, particularly among young 
women. To improve CC screening, the main challenge lies in 
both modifying screening facilities and getting women at risk 
to participate in screening programs. The current guidelines for 
age-appropriate cervical screening programs must be revised and 
the implementation of routinely performed HPV tests ahead of 
conizations—particularly in the case of young women—should 
been taken into consideration.
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